Search

Search Results

1. Imaging and dosimetry for alpha-particle emitter radiopharmaceutical therapy: improving radiopharmaceutical therapy by looking into the black box

   Radiopharmaceutical therapy using α-particle emitting radionuclides (αRPT) is a novel treatment modality that delivers highly potent alpha-particles...

   George Sgouros, Eric Frey, ... Wesley Bolch in European Journal of Nuclear Medicine and Molecular Imaging

   Article 16 November 2021
   

2. Structural modifications toward improved lead-203/lead-212 peptide-based image-guided alpha-particle radiopharmaceutical therapies for neuroendocrine tumors

   Purpose

   The lead-203 ( ²⁰³ Pb)/lead-212 ( ²¹² Pb) elementally identical radionuclide pair has gained significant interest in the field of image-guided...

   Dongyoul Lee, Mengshi Li, ... Michael K. Schultz in European Journal of Nuclear Medicine and Molecular Imaging

   Article Open access 13 November 2023
   

3. Good practices for ⁸⁹Zr radiopharmaceutical production and quality control

   Background

   During the previous two decades, PET imaging of biopharmaceuticals radiolabeled with zirconium-89 has become a consistent tool in...

   Thomas Erik Wuensche, Serge Lyashchenko, ... Danielle Vugts in EJNMMI Radiopharmacy and Chemistry

   Article Open access 11 May 2024
   

4. A first-in-human study of [⁶⁸Ga]Ga-CDI: a positron emitting radiopharmaceutical for imaging tumour cell death

   Purpose

   This study assesses human biodistribution, radiation dosimetry, safety and tumour uptake of cell death indicator labelled with ⁶⁸ Ga ([ ⁶⁸ Ga]Ga-...

   Ivan Ho Shon, Thomas Hennessy, ... Philip J. Hogg in European Journal of Nuclear Medicine and Molecular Imaging

   Article Open access 02 July 2022
   

5. Alpha Particle–Emitting Radiopharmaceuticals as Cancer Therapy: Biological Basis, Current Status, and Future Outlook for Therapeutics Discovery

   Critical advances in radionuclide therapy have led to encouraging new options for cancer treatment through the pairing of clinically useful...

   Ryan P. Coll, Scott J. Bright, ... H. Charles Manning in Molecular Imaging and Biology

   Article 16 October 2023
   

6. Recent advances and future perspectives in the therapeutics of prostate cancer

   Prostate cancer (PC) is one of the most common cancers in males and the fifth leading reason of death. Age, ethnicity, family history, and genetic...

   Ganji Lakshmi Varaprasad, Vivek Kumar Gupta, ... Yun Suk Huh in Experimental Hematology & Oncology

   Article Open access 22 September 2023
   

7. Current Status of PSMA-Targeted Radioligand Therapy in the Era of Radiopharmaceutical Therapy Acquiring Marketing Authorization

   Prostate-specific membrane antigen (PSMA) is highly expressed in PCa, which gradually increases in high-grade tumors, metastatic tumors, and tumors...

   So Won Oh, Minseok Suh, Gi Jeong Cheon in Nuclear Medicine and Molecular Imaging

   Article 20 August 2022
   

8. Proceedings of international symposium of trends in radiopharmaceuticals 2023 (ISTR-2023)

   The International Atomic Energy Agency (IAEA) held the 3rd International Symposium on Trends in Radiopharmaceuticals, (ISTR-2023) at IAEA...

   Amirreza Jalilian, Clemens Decristoforo, ... Peter J. H. Scott in EJNMMI Radiopharmacy and Chemistry

   Article Open access 10 November 2023
   

9. Guiding principles on the education and practice of theranostics

   Purpose

   The recent development and approval of new diagnostic imaging and therapy approaches in the field of theranostics have revolutionised nuclear...

   Thomas N. B. Pascual, Diana Paez, ... Andrew M. Scott in European Journal of Nuclear Medicine and Molecular Imaging

   Article Open access 08 March 2024

10. Formulation of a kit under Good Manufacturing Practices (GMP) for preparing [¹¹¹In]In-BnDTPA-trastuzumab-NLS injection: a theranostic agent for imaging and Meitner-Auger Electron (MAE) radioimmunotherapy of HER2-positive breast cancer

    Background

    ¹¹¹ In[In]-BnDTPA-trastuzumab-NLS is a radiopharmaceutical with theranostic applications for imaging and Meitner-Auger electron (MAE)...

    Conrad Chan, Vanessa Prozzo, ... Raymond M. Reilly in EJNMMI Radiopharmacy and Chemistry

    Article Open access 21 December 2022
    

11. Digital PET/CT allows for shorter acquisition protocols or reduced radiopharmaceutical dose in [¹⁸F]-FDG PET/CT

    Purpose

    To establish the feasibility of shorter acquisition times (and by analogy, applied activity) on tumour detection and lesion contrast in...

    Ian Alberts, Christos Sachpekidis, ... Axel Rominger in Annals of Nuclear Medicine

    Article Open access 07 February 2021
    

12. Practical considerations for navigating the regulatory landscape of non-clinical studies for clinical translation of radiopharmaceuticals

    Background

    The development of radiopharmaceuticals requires extensive evaluation before they can be applied in a diagnostic or therapeutic setting in...

    Aruna Korde, Renata Mikolajczak, ... Clemens Decristoforo in EJNMMI Radiopharmacy and Chemistry

    Article Open access 19 July 2022
    

13. National Cancer Institute support for targeted alpha-emitter therapy

    Background

    Radiopharmaceutical targeted therapy (RPT) has been studied for decades; however, recent clinical trials demonstrating efficacy have helped...

    Julie A. Hong, Martin Brechbiel, ... Jacek Capala in European Journal of Nuclear Medicine and Molecular Imaging

    Article 11 August 2021
    

14. Towards Improving the Efficacy of PSMA-Targeting Radionuclide Therapy for Late-Stage Prostate Cancer—Combination Strategies

    Purpose of Review

    [ ¹⁷⁷ Lu]Lu-PSMA-617 is a radiopharmaceutical that emits beta-minus radiation and targets prostate-specific membrane antigen...

    Daria Arbuznikova, Matthias Eder, ... Ann-Christin Eder in Current Oncology Reports

    Article Open access 20 October 2023
    

15. Highlight selection of radiochemistry and radiopharmacy developments by editorial board

    Background

    The Editorial Board of EJNMMI Radiopharmacy and Chemistry releases a biyearly highlight commentary to update the readership on trends in...

    Emerson Bernardes, Peter Caravan, ... Hua Zhu in EJNMMI Radiopharmacy and Chemistry

    Article Open access 26 April 2022
    

16. The aluminium-[¹⁸F]fluoride revolution: simple radiochemistry with a big impact for radiolabelled biomolecules

    The aluminium-[ ¹⁸ F]fluoride ([ ¹⁸ F]AlF) radiolabelling method combines the favourable decay characteristics of fluorine-18 with the convenience and...

    Stephen J. Archibald, Louis Allott in EJNMMI Radiopharmacy and Chemistry

    Article Open access 26 August 2021
    

17. Radiopharmaceuticals: navigating the frontier of precision medicine and therapeutic innovation

    This review article explores the dynamic field of radiopharmaceuticals, where innovative developments arise from combining radioisotopes and...

    Shivang Dhoundiyal, Shriyansh Srivastava, ... Farzad Taghizadeh-Hesary in European Journal of Medical Research

    Article Open access 05 January 2024
    

18. Fibroblast activation protein targeted radiotherapy induces an immunogenic tumor microenvironment and enhances the efficacy of PD-1 immune checkpoint inhibition

    Purpose

    FAP is a membrane-bound protease under investigation as a pan-cancer target, given its high levels in tumors but limited expression in normal...

    Dirk Zboralski, Frank Osterkamp, ... Minh Nguyen in European Journal of Nuclear Medicine and Molecular Imaging

    Article Open access 22 April 2023
    

19. Influence of metabolic tumor burden on reference tissues’ standardized uptake values in ¹⁸F-FDG PET/CT sequential imaging

    Background

    Extremely hypermetabolic neoplastic tissues have been hypothesized to act as a “sink” reducing the amount of radiopharmaceutical available...

    Ahmed Badawy, Marwa Mohamed Maamoun, ... Hoda Anwar in Egyptian Journal of Radiology and Nuclear Medicine

    Article Open access 17 November 2023
    

20. A suitable time point for quantifying the radiochemical purity of ²²⁵Ac-labeled radiopharmaceuticals

    Background

    As ²²⁵ Ac-labeled radiopharmaceuticals continue to show promise as targeted alpha therapeutics, there is a growing need to standardize...

    James M. Kelly, Alejandro Amor-Coarasa, ... John W. Babich in EJNMMI Radiopharmacy and Chemistry

    Article Open access 20 December 2021